Burow Kristina

Arch Venture Partners XIII, LLC (Director) purchased 1,250,000 shares of KARD at $16.00; now holds 15,042,035 shares.

Arch Venture Partners XIII, LLC acquired 1,250,000 shares for $20,000,000.00, expanding its stake in Kardigan from 13,792,035 shares to 15,042,035 shares—a 9.1% increase in holdings. The purchase occurred at $16.00 per share, while the current market price stands at $22.03 as of 2026-06-24, four trading days after Kardigan's recent listing. This transaction represents a material expansion of an already substantial directorial position, with the entity now holding 15,042,035 shares outright.

ARCH Venture Partners XII acquires over 5M shares in SPTX IPO aftermath; major institutional vote of confidence at listing price

ARCH Venture Partners XII, a 10% beneficial owner of Seaport Therapeutics, executed a substantial open-market purchase of over 5 million shares on the stock's second trading day—a significant institutional commitment that coincides with the company's recent IPO. The timing is notable: the fund is buying at the listing price level after having already participated in the private placement rounds that likely seeded its beneficial ownership stake. This isn't insider knowledge driving the trade, but rather portfolio capital allocation—ARCH is doubling down on its conviction in the biotech therapeutics opportunity the company represents. The purchase reflects institutional confidence that the newly public shares offer fair value at current levels, which could signal that the market's initial pricing is reasonable from the fund's perspective.

ARCH Venture Fund XIII acquired 488,090 shares of LYEL at $25.61 for $12.5M, raising stake to 1.43M shares amid unprofitable fundamentals.

ARCH Venture Fund XIII, a 10% shareholder, purchased 488,090 shares at $25.61 on 2026-03-06, increasing its stake by 52.0% from 938,438 to 1.43M shares. The transaction occurred at a price 33.9% below the 52-week high of $38.60 but 228% above the 52-week low of $7.80, near recent momentum (+12.3% over 30 days, -12.9% over 90 days). The acquisition is notable given the company's deteriorating fundamentals: LYEL generated only $15.0K in latest-quarter revenue (annualized run-rate concerns), posted a net loss of $-38.8M, and experienced -53.1% annual revenue decline with sustained unprofitability. A venture capital anchor doubling down on a cash-burn biotech asset during a revenue collapse warrants scrutiny of the company's clinical/financing runway and the strategic rationale underlying this substantial $12.5M incremental commitment.

Director Burow buys 1,915,700 shares of NMRA at $2.61 for $5.0M, boosting stake 46.4%; stock down 81.7% from $13.64 high but up 42.0% in 30 days.

Kristina Burow, a Director, purchased 1,915,700 shares at $2.61 on 2025-10-27 for a total of $5,000,000, increasing her holdings from 4,131,207 to 6,046,907 shares (a 46.4% increase in stake). This represents a substantial personal capital commitment at a deeply depressed valuation—the stock currently trades at $2.50, down 81.7% from its 52-week high of $13.64. Notably, 2 other insiders also bought within the past 14 days, establishing a cluster buy pattern. Her prior 5 buys at NMRA were all well-timed at the 90-day mark with returns ranging from +48.5% to +61.2%, and her cross-ticker track record shows an 88.89% 90-day win rate, though the company itself reported negative net income of $-52,731,000 for the most recent full fiscal year. The recent 30-day and 90-day price rallies (+42.0% and +27.6% respectively) follow this accumulation pattern, warranting close examination of what catalysts or operational developments may be signaling to insiders at this stage.

ARCH Venture Partners X bought 3,030,300 shares of PRME at $3.30 ($10.0M), boosting stake 94.7% to 6,230,300 shares

ARCH Venture Partners X, a 10% owner of Prime Medicine, purchased 3,030,300 shares at $3.30 on 2025-08-01 for $9,999,990.00, expanding its position from 3,200,000 to 6,230,300 shares. The company remains deeply unprofitable with a net loss of $-51,890,000.00 against minimal revenue of $1,454,000.00, though the stock has recovered +31.6% over 30 days and +140.5% over 90 days from a 52-week low. The prior ARCH purchase at this ticker on 2024-02-15 achieved positive returns at both the 30-day (+14.6%) and 90-day (+8.2%) intervals, establishing a successful historical precedent. A cluster of 3 other insiders also bought within the past 14 days, suggesting aligned investor interest despite the company's ongoing cash-burn profile.

Director Burow purchases 2,222,222 shares ($40.0M at $18.00) within 2-day listing; part of 3-insider cluster buy

Kristina Burow, a director at Metsera Inc., purchased 2,222,222 shares in two separate transactions on 2025-02-03 for $39,999,996.00 at $18.00 per share—equivalent to a 36.5% increase in her shareholdings from 6.09M to 8.31M shares. This $40.0M commitment by a board member occurs in a newly listed stock (2 trading days post-IPO) and coincides with a cluster pattern of insider buying: 2 other insiders also acquired shares within the past 14 days. The current market price of $27.80 reflects early trading dynamics post-listing. This filing contains a derivative conversion flag; the shareholder's full derivative position resides in Form 4 Table II, which is not yet populated in our database, so the Table I holdings reported here represent only the cash-settled or converted portion of her total position.